The emergence of competitive rare diseases
Expanding upon how the rare disease space has developed since early ODs were approved, roundtable participants assessed how commercialization strategies have...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Price and access decisions are critical for maximizing the lifecycle value of an asset or franchise. Life sciences companies seeking to develop successful pricing and access strategies must navigate the complex and evolving interactions between customers and products, and must ensure that their decisions balance strategic and financial goals while enabling appropriate access and reimbursement to medical providers, patients, and caregivers.
Expanding upon how the rare disease space has developed since early ODs were approved, roundtable participants assessed how commercialization strategies have...
In the first of a new series of CRA Insights on this topic, Aaron Everitt looks at how Keytruda and other branded and biosimilar manufacturers are preparing...
CRA is a proud sponsor of the epicenter of the specialty pharmacy industry event. Becky Davis presents the session titled “GLP-1s: Riding the Wave of...
CRA is a proud sponsor of the event covering market access, pricing, reimbursement, rare diseases, health technology assessments, health economics and outcomes...